Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers
Medinno has raised more than RMB 200 million in a Series A financing led by Sunshine Ronghui Capital, giving the company fresh funding to develop MDI-1228, a topical drug candidate for diabetic foot ulcers and other conditions. The proceeds will support…
BioNTech and OncoC4’s Gotistobart Nearly Doubles Survival in Previously Treated Squamous NSCLC
Updated PRESERVE-003 data showed median overall survival of 18.5 months with the CTLA-4 antibody, compared with 10 months for docetaxel. The result is encouraging, but confirmation must come from the ongoing pivotal stage of the Phase 3 trial. BioNTech…
Novartis Acquires Global Rights to Sironax Brain-Delivery Platform for $125 Million
The Swiss pharmaceutical group has exercised its option to acquire Sironax’s technology for transporting large therapeutic molecules across the blood-brain barrier. Novartis has exercised its exclusive option to acquire full global rights to Sironax’s…
GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million
GSK is expanding its relationship with China’s Chimagen Biosciences, agreeing to acquire global rights to an experimental trispecific T-cell engager for multiple myeloma in a transaction worth up to $750 million. The agreement, announced September 15,…
Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial
Forlong Biotech has completed the second close of its Pre-B financing, bringing the round’s total to nearly RMB 200 million. Fosun Health Capital’s new drug fund led the latest close, which raised more than RMB 100 million, according to Chinese financing…
ByteDance’s AI Drug Discovery Spinout Anew Labs Reportedly Raises $290 Million
Anew Labs, the AI drug discovery company spun out of TikTok owner ByteDance, has reportedly completed a $290 million first independent financing round. China’s PEdaily reported the raise citing sources; Reuters separately reported the same amount based…
RemeGen and AbbVie’s RC148 Delivers 90% Response Rate in a Phase 1b Trial of First-Line Squamous NSCLC
The PD-1/VEGF bispecific antibody produced high response rates with chemotherapy across squamous and non-squamous lung cancer cohorts, supporting its advancement into Phase 3 development. RemeGen and AbbVie have reported strong early clinical results for…
Roche and MediLink’s Tam-Peli Reduces Death Risk by 54% in Phase 3 Small-Cell Lung Cancer Trial
Roche and MediLink Therapeutics have reported a substantial survival benefit for tambotatug pelitecan, the experimental B7-H3-targeted antibody-drug conjugate known as Tam-Peli, in patients with relapsed small-cell lung cancer. In the Chinese Phase 3…
Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose
Biokin’s U.S. subsidiary SystImmune has reported new global Phase 1 results for iza-bren, its EGFR×HER3 bispecific antibody-drug conjugate (ADC), supporting selection of a dose for registrational testing in patients with previously treated EGFR-mutated…
GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial
GSK and Hansoh Pharma’s B7-H3-directed antibody-drug conjugate risvutatug rezetecan delivered a striking survival benefit in relapsed small-cell lung cancer, potentially setting a new benchmark for a disease in which treatment progress has historically…